bladder-cancer

health

Small Phase 2a Trial Reports Higher Responses With Nivolumab–Visugromab in Bladder Cancer

In the 31-patient exploratory GDFATHER-NEO trial, nivolumab plus visugromab was associated with higher pathological and radiographic response rates than nivolumab plus placebo before bladder surgery. The small, nonrandomized study was not designed to establish long-term benefit.

2026-10-24T17:05:35+05:30

health

Study finds urine RNA assay detects bladder cancer with 95% sensitivity and 90% specificity

A Nature Medicine study reports that urine cell-free RNA sequencing detected localized bladder cancer with 95% sensitivity at 90% specificity. The researchers also investigated its potential for detecting residual disease and predicting response to bladder treatments.

2026-10-02T19:11:48+05:30